Hennion & Walsh Asset Management, Inc.
Position in AKBA — Akebia Therapeutics, Inc.
CIK 1861642
Parsippany, NJ
Position in AKBA
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$880,221
+$76,894 QoQ
Shares Held
633,253
+26.9% QoQ
Ownership
0.236%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#30
of 170 holders
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in AKBA Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Hennion & Walsh Asset Management, Inc. holds $39,326,268 across 12 Drug Manufacturers - Specialty & Generic names. AKBA ranks #8 (2.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TEVA |
Teva Pharmaceutical Industries Ltd
|
337,044 | $10,151,765 | |
| 2 | INDV |
Indivior Pharmaceuticals, Inc.
|
330,691 | $10,079,461 | |
| 3 | SUPN |
Supernus Pharmaceuticals, Inc.
|
88,454 | $4,572,187 | |
| 4 | UTHR |
UNITED THERAPEUTICS Corp
|
6,195 | $3,673,511 | |
| 5 | PCRX |
Pacira BioSciences, Inc.
|
155,396 | $3,511,949 | |
| 6 | KNSA |
Kiniksa Pharmaceuticals International, plc
|
67,341 | $3,242,469 | |
| 7 | BCRX |
Biocryst Pharmaceuticals Inc
|
113,881 | $1,084,147 | |
| 8 | AKBA |
Akebia Therapeutics, Inc.
This page
|
633,253 | $880,221 |
All Filings in AKBA
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $880,221 | 633,253 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $803,327 | 498,961 | Shares | Sole | 2026-01-14 | |
| No filing history on record for this holder in this stock. | ||||||